U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Go back to U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)| Merck & Co. (NYSE: MRK) | Delayed: 148.78 +0.80 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.98 | 52 Week High | $65.46 | |||
| Open | $148.06 | 52 Week Low | $47.97 | |||
| Day High | $149.98 | P/E | 101.21 | |||
| Day Low | $147.48 | EPS | $1.47 | |||
| Volume | 8,290,254 | |||||
